Diagonal Therapeutics

Executive Summary

Diagonal Therapeutics is a preclinical-stage biotechnology company pioneering the discovery and development of agonist antibodies that activate receptor complexes by mimicking natural ligand signaling. Founded in 2022 and headquartered in Cambridge, MA, the company leverages its proprietary platform to identify antibodies that restore pathway function, with initial focus on immunology and cardiovascular disorders. Diagonal has raised $253 million in total funding, reflecting strong investor confidence in its novel approach. The company's platform has the potential to address a wide range of diseases where receptor activation is therapeutically beneficial, positioning it as a leader in the agonist antibody space. As it advances its pipeline toward clinical development, Diagonal represents a high-risk, high-reward opportunity contingent on successful preclinical-to-clinical translation.

Upcoming Catalysts (preview)

• Q4 2026Lead Program IND Filing60% success
• TBDInitial Phase 1 Data for Lead Candidate40% success
• Q2 2026Potential Partnership or Licensing Deal50% success